Urogen Pharma (NASDAQ:URGN) – Stock analysts at Jefferies Group reduced their Q4 2017 earnings per share estimates for shares of Urogen Pharma in a report issued on Wednesday. Jefferies Group analyst M. Andrews now anticipates that the company will post earnings per share of ($0.67) for the quarter, down from their prior estimate of ($0.64). Jefferies Group currently has a “Buy” rating and a $37.00 price target on the stock. Jefferies Group also issued estimates for Urogen Pharma’s FY2018 earnings at ($2.47) EPS, FY2019 earnings at ($2.59) EPS and FY2020 earnings at ($1.47) EPS.

Several other analysts have also issued reports on URGN. Cowen and Company reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Wednesday. UBS AG lowered shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday. CIBC reaffirmed an “outperform” rating and set a $51.00 price target (up from $32.00) on shares of Urogen Pharma in a research report on Wednesday. Oppenheimer Holdings, Inc. set a $32.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research lowered shares of Urogen Pharma from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $36.80.

COPYRIGHT VIOLATION WARNING: “Q4 2017 Earnings Estimate for Urogen Pharma (URGN) Issued By Jefferies Group” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/17/q4-2017-earnings-estimate-for-urogen-pharma-urgn-issued-by-jefferies-group.html.

Urogen Pharma (NASDAQ URGN) traded up $0.75 during midday trading on Friday, reaching $41.00. 176,311 shares of the company’s stock traded hands, compared to its average volume of 62,480. Urogen Pharma has a 1 year low of $13.01 and a 1 year high of $44.63.

Several hedge funds have recently added to or reduced their stakes in the stock. Spark Investment Management LLC acquired a new stake in Urogen Pharma during the second quarter worth about $856,000. Menora Mivtachim Holdings LTD. acquired a new stake in Urogen Pharma during the second quarter worth about $2,331,000. LLBH Private Wealth Management LLC acquired a new stake in Urogen Pharma during the second quarter worth about $695,000. Alps Advisors Inc. acquired a new stake in Urogen Pharma during the second quarter worth about $195,000. Finally, Jennison Associates LLC acquired a new stake in Urogen Pharma during the second quarter worth about $3,168,000. Institutional investors and hedge funds own 40.55% of the company’s stock.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.